Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures

 Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures

Shots:

  • The companies terminated their collaboration that centered around bintrafusp alfa as the drug failed to show potential in INTR@PID Lung 037 study as the 2L treatment for metastatic BTC
  • The termination followed a decision made by the two companies to discontinue the development of bintrafusp alfa as a 1L therapy for patients with stage IV NSCLC and high expression of PD-L1
  • IDSM board recommended the termination of the P-III study in which bintrafusp + Keytruda was not likely to meet its 1EPs of PFS

Click here to­ read full press release/ article | Ref: Merck KGaA | Image: CHEManager

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post